Acta Scientific Orthopaedics (ASOR)(ISSN: 2581-8635)

Research Article Volume 4 Issue 6

Effect of Sublingual Piroxicam on Hypoxia in Cytokine Storm Induced Covid 19 Pneumonia - Descriptive Study of Clinicians’ Experiences in 2003 Consecutive Cases

L Prakash1*, Arvind Diwaker Jain2, Shabir Dhar3 and Sajid Jamal4

1Consultant Orthopaedic Surgeon, Palakkad, Kerala, India
2Consultant Orthopaedic Surgeon, Lalitpur, Uttar Pradesh, India
3Consultant Orthopaedic Surgeon, Srinagar, India
4Consultant Orthopaedic Surgeon, Calicut, Kerala, India

*Corresponding Author: L Prakash, Consultant Orthopaedic Surgeon, Palakkad, Kerala, India.

Received: May 11, 2021; Published: May 20, 2021

Abstract

Pulmonary compromise and rapidly diminishing serum oxygen levels (SpO2), affects a significant number of patients suffering from Covid 19, and often necessities hospitalisation and administration of oxygen! Cytokine storm has been identified as one of the principal causes of this diminution of oxygen concentrations. Anti-inflammatory agents are known to assist in control of cytokine storms, and the current study is an observation of 2003 Covid 19 patients, who were administered 20 mg sublingual cuboidal crystals of Piroxicam daily for five days. 134 participating clinicians shared their experience with the molecule. It was observed that Piroxicam was capable of controlling cytokine storm, and rapidly improving oxygen saturation in over 90% of patients and the effect of a single tablet was sustained for over 24 hours.

 

Keywords: Sublingual Piroxicam; Hypoxia; Cytokine Storm; Covid 19 Pneumonia

References

  1. Singh TU., et al. “Drug repurposing approach to fight COVID-19”. Pharmacological Reports 6 (2020): 1479-1508.
  2. Jennifer S Chen., et al. “Nonsteroidal Anti-inflammatory Drugs Dampen the Cytokine and Antibody Response to SARS-CoV-2 Infection”. Journal of Virology 7 (2021).
  3. DO Sordelli., et al. “Piroxicam treatment protects mice from lethal pulmonary challenge with Pseudomonas aeruginosa”. Journal of Infectious Disease 2 (1989): 232-238.
  4. Mostafa A., et al. “FDA- Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2”. Pharmaceuticals12 (2020): 443.
  5. https://m.facebook.com/groups/medicalalliance/permalink/10158272423866302/
  6. Sun X., et al. “Cytokine storm intervention in the early stages of COVID-19 pneumonia”. Cytokine and Growth Factor Reviews 53 (2020): 38-42.
  7. Akilesh SM., et al. “Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight”. Current Pharmaceutical Biotechnology 2 (2021): 192-199.

Citation

Citation: L Prakash., et al. “Effect of Sublingual Piroxicam on Hypoxia in Cytokine Storm Induced Covid 19 Pneumonia - Descriptive Study of Clinicians’ Experiences in 2003 Consecutive Cases". Acta Scientific Orthopaedics 4.6 (2021): 78-81.




Metrics

Acceptance rate33%
Acceptance to publication20-30 days
Impact Factor0.614

Indexed In



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is September 30, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US